3'-deoxy-3'-18F-fluorothymidine (FLT) PET/CT to guide therapy with epidermal growth factor receptor (EGFR) antagonists and Bcl-xL inhibitors in non-small cell lung cancer (614 views)
J Nucl Med (ISSN: 0161-5505, 1535-5667, 1535-5667electronic), 2012 Mar 1; 53(3): 443-450.
Export to BibTeX Export to EndNote
Paper type: Journal Article, Research Support, Non-U. S. Gov'T,
Impact factor: 5.774, 5-year impact factor: 6.402
Url: http://www.scopus.com/inward/record.url?eid=2-s2.0-84858608489&partnerID=40&md5=7f9fae30e4a8b0e2e9171ad4f3c1cc5c
Keywords: 18f-Flt, Egfr, Lung Cancer, Pet Ct, Fluorothymidine F 18, Cl 387 785, Epidermal Growth Factor Receptor Kinase Inhibitor, Erlotinib, Ki 67 Antigen, N [4 (3 Bromoanilino) 6 Quinazolinyl] 2 Butynamide, Navitoclax, Unclassified Drug, Wz 4002, Dideoxynucleoside Derivative, Aniline Derivative, Antineoplastic Agent, Diagnostic Agent, Protein Bcl X, Protein Kinase Inhibitor, Quinazoline Derivative, Radiopharmaceutical Agent, Sulfonamide, Animal Experiment, Animal Model, Animal Tissue, Apoptosis, Article, Cancer Cell Culture, Cell Cycle Arrest, Cell Cycle G1 Phase, Cell Cycle S Phase, Computer Assisted Emission Tomography, Concentration Response, Controlled Study, Dose Response, Drug Efficacy, Drug Megadose, Drug Resistance, Drug Sensitivity, Drug Tumor Level, Gene Mutation, Human, Human Cell, Image Analysis, Immunohistochemistry, Isotope Labeling, Low Drug Dose, Lung Non Small Cell Cancer, Mouse, Nonhuman, Priority Journal, Quantitative Study, Tumor Xenograft, Bagg Albino Mouse, Cell Proliferation, Drug Antagonism, Drug Effect, Female, Image Processing, Lung Tumor, Methodology, Scintiscanning, Tumor Cell Line, Western Blotting, Aniline Compounds, Bcl-X Protein, Carcinoma, Non-Small-Cell Lung, Computer-Assisted, Lung Neoplasms, Inbred Balb C, Positron-Emission Tomography And Computed Tomography, Aniline Compounds Therapeutic Use, Antineoplastic Agents Therapeutic Use, Apoptosis Drug Effects, Non-Small-Cell Lung Drug Therapy Radionuclide Imaging, Cell Proliferation Drug Effects, Dideoxynucleosides Diagnostic Use, Lung Neoplasms Drug Therapy Radionuclide Imaging, Multimodal Imaging Methods, Protein Kinase Inhibitors Therapeutic Use, Quinazolines Therapeutic Use, Radiopharmaceuticals Diagnostic Use, Epidermal Growth Factor Antagonists, Sulfonamides Therapeutic Use, X-Ray Computed, Bcl-X Protein Antagonists,
Affiliations:
*** IBB - CNR ***
Institute of Biostructures and Bioimages, National Research Council, Naples, Italy
Department of Biomorphological and Functional Sciences, University of Naples Federico II, Edificio 10, Via S. Pansini 5, 80131 Naples, Italy
References:
Pao, W., Chmielecki, J., Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer (2010) Nat Rev Cancer, 10, pp. 760-77
Gazdar, A.F., Activating and resistance mutations of EGFR in non-small-cell lung cancer: Role in clinical response to EGFR tyrosine kinase inhibitors (2009) Oncogene, 28 (SUPPL.), pp. S24-S31
Lynch, T.J., Bell, D.W., Sordella, R., Gurubhagavatula, S., Okimoto, R.A., Brannigan, B.W., Harris, P.L., Haber, D.A., Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non-Small-Cell Lung Cancer to Gefitinib (2004) New England Journal of Medicine, 350 (21), pp. 2129-2139. , DOI 10.1056/NEJMoa040938
Paez, J.G., Janne, P.A., Lee, J.C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Meyerson, M., EGFR mutations in lung, cancer: Correlation with clinical response to gefitinib therapy (2004) Science, 304 (5676), pp. 1497-1500. , DOI 10.1126/science.1099314
Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Varmus, H., EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib (2004) Proceedings of the National Academy of Sciences of the United States of America, 101 (36), pp. 13306-13311. , DOI 10.1073/pnas.0405220101
Sharma, S.V., Bell, D.W., Settleman, J., Epidermal growth factor receptor mutations in lung cancer (2007) Nat Rev Cancer, 7, pp. 169-181
Kobayashi, S., Boggon, T.J., Dayaram, T., Janne, P.A., Kocher, O., Meyerson, M., Johnson, B.E., Halmos, B., EGFR mutation and resistance of non-small-cell lung cancer to gefitinib (2005) New England Journal of Medicine, 352 (8), pp. 786-792. , DOI 10.1056/NEJMoa044238
Engelman, J.A., Janne, P.A., Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer (2008) Clin Cancer Res, 14, pp. 2895-2899
Yun, C.-H., Mengwasser, K.E., Toms, A.V., Woo, M.S., Greulich, H., Wong, K.-K., Meyerson, M., Eck, M.J., The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP (2008) Proceedings of the National Academy of Sciences of the United States of America, 105 (6), pp. 2070-2075. , http://www.pnas.org/cgi/reprint/105/6/2070, DOI 10.1073/pnas.0709662105
Zhou, W., Ercan, D., Chen, L., Novel mutant-selective EGFR kinase inhibitors against EGFR T790M (2009) Nature, 462, pp. 1070-1074
Engelman, J.A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Joon, O.P., Lindeman, N., Janne, P.A., MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling (2007) Science, 316 (5827), pp. 1039-1043. , DOI 10.1126/science.1141478
Bean, J., Brennan, C., Shih, J.Y., MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib (2007) Proc Natl Acad Sci USA, 104, pp. 20932-20937
Sequist, L.V., Von Pawel, J., Garmey, E.G., Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer (2011) J Clin Oncol, 29, pp. 3307-3315
Deng, J., Shimamura, T., Perera, S., Proapoptotic BH3-only BCL-2 family protein BIM connects death signaling from epidermal growth factor receptor inhibition to the mitochondrion (2007) Cancer Res, 67, pp. 11867-11875
Costa, D.B., Halmos, B., Kumar, A., BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations (2007) PLoS Med, 4, pp. 1669-1679
Kuroda, J., Puthalakath, H., Cragg, M.S., Kelly, P.N., Bouillet, P., Huang, D.C.S., Kimura, S., Strasser, A., Bim and Bad mediated imatinib-induced killing of Bcr/Abl + leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic (2006) Proceedings of the National Academy of Sciences of the United States of America, 103 (40), pp. 14907-14912. , DOI 10.1073/pnas.0606176103
Gong, Y., Somwar, R., Politi, K., Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas (2007) PLoS Med, 4, pp. e294
Tan, N., Malek, M., Zha, J., Navitoclax enhances the efficacy of taxanes in non-small cell lung cancer models (2011) Clin Cancer Res, 17, pp. 1394-1404
Gandhi, L., Camidge, D.R., Ribeiro De Oliveira, M., Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors (2011) J Clin Oncol, 29, pp. 909-916
Zannetti, A., Iommelli, F., Fonti, R., Gefitinib induction of in vivo detectable signals by Bcl-2/Bcl-xL modulation of inositol trisphosphate receptor type 3 (2008) Clin Cancer Res, 14, pp. 5209-5219
Oh, S.J., Mosdzianowski, C., Chi, D.Y., Fully automated synthesis system of 3′-deoxy-3′-[ 18F]fluorothymidine (2004) Nucl Med Biol, 31, pp. 803-809
Waldherr, C., Mellinghoff, I.K., Tran, C., Halpern, B.S., Rozengurt, N., Safaei, A., Weber, W.A., Czernin, J., Monitoring antiproliferative responses to kinase inhibitor therapy in mice with 3′-deoxy-3′- 18F-fluorothymidine PET (2005) Journal of Nuclear Medicine, 46 (1), pp. 114-120
Wang, Y., Seidel, J., Tsui, B.M.W., Vaquero, J.J., Pomper, M.G., Performance evaluation of the GE healthcare eXplore VISTA dual-ring small-animal PET scanner (2006) Journal of Nuclear Medicine, 47 (11), pp. 1891-1900. , http://jnm.snmjournals.org/cgi/reprint/47/11/1891
Tseng, J.R., Kang, K.W., Dandekar, M., Preclinical efficacy of the c-Met inhibitor CE-355621 in a U87 MG mouse xenograft model evaluated by 18F-FDG small-animal PET (2008) J Nucl Med, 49, pp. 129-134
Wei, L.H., Su, H., Hildebrandt, I.J., Changes in tumor metabolism as readout for mammalian target of rapamycin kinase inhibition by rapamycin in glioblastoma (2008) Clin Cancer Res, 14, pp. 3416-3426
Zannetti, A., Del, V.S., Carriero, M.V., Fonti, R., Franco, P., Botti, G., D'Aiuto, G., Salvatore, M., Coordinate up-regulation of Sp1 DNA-binding activity and urokinase receptor expression in breast carcinoma (2000) Cancer Research, 60 (6), pp. 1546-1551
Ullrich, R.T., Zander, T., Neumaier, B., Early detection of erlotinib treatment response in NSCLC by 3′-deoxy-3′-[F]-fluoro-l-thymidine ([F]FLT) positron emission tomography (PET) (2008) PLoS One, 3, pp. e3908
Sequist, L.V., Waltman, B.A., Dias-Santagata, D., Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors (2011) Sci Transl Med, 3, pp. 75ra26
Zander, T., Scheffler, M., Nogova, L., Early prediction of nonprogression in advanced non-small-cell lung cancer treated with erlotinib by using [ 18F]fluorodeoxyglucose and [ 18F]fluorothymidine positron emission tomography (2011) J Clin Oncol, 29, pp. 1701-1708
Cullinane, C., Dorow, D.S., Jackson, S., Differential 18F-FDG and 3′-deoxy-3′- 18F-fluorothymidine PET responses to pharmacologic inhibition of the c-MET receptor in preclinical tumor models (2011) J Nucl Med, 52, pp. 1261-1267
Yang, M., Gao, H., Yan, Y., PET imaging of early response to the tyrosine kinase inhibitor ZD4190 (2011) Eur J Nucl Med Mol Imaging, 38, pp. 1237-1247
Gazdar, A. F., Activating and resistance mutations of EGFR in non-small-cell lung cancer: Role in clinical response to EGFR tyrosine kinase inhibitors (2009) Oncogene, 28 (SUPPL.), pp. S24-S31
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haber, D. A., Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non-Small-Cell Lung Cancer to Gefitinib (2004) New England Journal of Medicine, 350 (21), pp. 2129-2139. , DOI 10. 1056/NEJMoa040938
Paez, J. G., Janne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Meyerson, M., EGFR mutations in lung, cancer: Correlation with clinical response to gefitinib therapy (2004) Science, 304 (5676), pp. 1497-1500. , DOI 10. 1126/science. 1099314
Sharma, S. V., Bell, D. W., Settleman, J., Epidermal growth factor receptor mutations in lung cancer (2007) Nat Rev Cancer, 7, pp. 169-181
Engelman, J. A., Janne, P. A., Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer (2008) Clin Cancer Res, 14, pp. 2895-2899
Yun, C. -H., Mengwasser, K. E., Toms, A. V., Woo, M. S., Greulich, H., Wong, K. -K., Meyerson, M., Eck, M. J., The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP (2008) Proceedings of the National Academy of Sciences of the United States of America, 105 (6), pp. 2070-2075. , http: //www. pnas. org/cgi/reprint/105/6/2070, DOI 10. 1073/pnas. 0709662105
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Joon, O. P., Lindeman, N., Janne, P. A., MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling (2007) Science, 316 (5827), pp. 1039-1043. , DOI 10. 1126/science. 1141478
Sequist, L. V., Von Pawel, J., Garmey, E. G., Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer (2011) J Clin Oncol, 29, pp. 3307-3315
Costa, D. B., Halmos, B., Kumar, A., BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations (2007) PLoS Med, 4, pp. 1669-1679
Oh, S. J., Mosdzianowski, C., Chi, D. Y., Fully automated synthesis system of 3 -deoxy-3 - [18F] fluorothymidine (2004) Nucl Med Biol, 31, pp. 803-809
Tseng, J. R., Kang, K. W., Dandekar, M., Preclinical efficacy of the c-Met inhibitor CE-355621 in a U87 MG mouse xenograft model evaluated by 18F-FDG small-animal PET (2008) J Nucl Med, 49, pp. 129-134
Wei, L. H., Su, H., Hildebrandt, I. J., Changes in tumor metabolism as readout for mammalian target of rapamycin kinase inhibition by rapamycin in glioblastoma (2008) Clin Cancer Res, 14, pp. 3416-3426
Ullrich, R. T., Zander, T., Neumaier, B., Early detection of erlotinib treatment response in NSCLC by 3 -deoxy-3 - [F] -fluoro-l-thymidine ([F] FLT) positron emission tomography (PET) (2008) PLoS One, 3, pp. e3908
Sequist, L. V., Waltman, B. A., Dias-Santagata, D., Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors (2011) Sci Transl Med, 3, pp. 75ra26
J Nucl Med (ISSN: 0161-5505, 1535-5667, 1535-5667electronic), 2012 Mar 1; 53(3): 443-450.
Export to BibTeX Export to EndNote
Paper type: Journal Article, Research Support, Non-U. S. Gov'T,
Impact factor: 5.774, 5-year impact factor: 6.402
Url: http://www.scopus.com/inward/record.url?eid=2-s2.0-84858608489&partnerID=40&md5=7f9fae30e4a8b0e2e9171ad4f3c1cc5c
Keywords: 18f-Flt, Egfr, Lung Cancer, Pet Ct, Fluorothymidine F 18, Cl 387 785, Epidermal Growth Factor Receptor Kinase Inhibitor, Erlotinib, Ki 67 Antigen, N [4 (3 Bromoanilino) 6 Quinazolinyl] 2 Butynamide, Navitoclax, Unclassified Drug, Wz 4002, Dideoxynucleoside Derivative, Aniline Derivative, Antineoplastic Agent, Diagnostic Agent, Protein Bcl X, Protein Kinase Inhibitor, Quinazoline Derivative, Radiopharmaceutical Agent, Sulfonamide, Animal Experiment, Animal Model, Animal Tissue, Apoptosis, Article, Cancer Cell Culture, Cell Cycle Arrest, Cell Cycle G1 Phase, Cell Cycle S Phase, Computer Assisted Emission Tomography, Concentration Response, Controlled Study, Dose Response, Drug Efficacy, Drug Megadose, Drug Resistance, Drug Sensitivity, Drug Tumor Level, Gene Mutation, Human, Human Cell, Image Analysis, Immunohistochemistry, Isotope Labeling, Low Drug Dose, Lung Non Small Cell Cancer, Mouse, Nonhuman, Priority Journal, Quantitative Study, Tumor Xenograft, Bagg Albino Mouse, Cell Proliferation, Drug Antagonism, Drug Effect, Female, Image Processing, Lung Tumor, Methodology, Scintiscanning, Tumor Cell Line, Western Blotting, Aniline Compounds, Bcl-X Protein, Carcinoma, Non-Small-Cell Lung, Computer-Assisted, Lung Neoplasms, Inbred Balb C, Positron-Emission Tomography And Computed Tomography, Aniline Compounds Therapeutic Use, Antineoplastic Agents Therapeutic Use, Apoptosis Drug Effects, Non-Small-Cell Lung Drug Therapy Radionuclide Imaging, Cell Proliferation Drug Effects, Dideoxynucleosides Diagnostic Use, Lung Neoplasms Drug Therapy Radionuclide Imaging, Multimodal Imaging Methods, Protein Kinase Inhibitors Therapeutic Use, Quinazolines Therapeutic Use, Radiopharmaceuticals Diagnostic Use, Epidermal Growth Factor Antagonists, Sulfonamides Therapeutic Use, X-Ray Computed, Bcl-X Protein Antagonists,
Affiliations:
*** IBB - CNR ***
Institute of Biostructures and Bioimages, National Research Council, Naples, Italy
Department of Biomorphological and Functional Sciences, University of Naples Federico II, Edificio 10, Via S. Pansini 5, 80131 Naples, Italy
References:
Pao, W., Chmielecki, J., Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer (2010) Nat Rev Cancer, 10, pp. 760-77
Gazdar, A.F., Activating and resistance mutations of EGFR in non-small-cell lung cancer: Role in clinical response to EGFR tyrosine kinase inhibitors (2009) Oncogene, 28 (SUPPL.), pp. S24-S31
Lynch, T.J., Bell, D.W., Sordella, R., Gurubhagavatula, S., Okimoto, R.A., Brannigan, B.W., Harris, P.L., Haber, D.A., Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non-Small-Cell Lung Cancer to Gefitinib (2004) New England Journal of Medicine, 350 (21), pp. 2129-2139. , DOI 10.1056/NEJMoa040938
Paez, J.G., Janne, P.A., Lee, J.C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Meyerson, M., EGFR mutations in lung, cancer: Correlation with clinical response to gefitinib therapy (2004) Science, 304 (5676), pp. 1497-1500. , DOI 10.1126/science.1099314
Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Varmus, H., EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib (2004) Proceedings of the National Academy of Sciences of the United States of America, 101 (36), pp. 13306-13311. , DOI 10.1073/pnas.0405220101
Sharma, S.V., Bell, D.W., Settleman, J., Epidermal growth factor receptor mutations in lung cancer (2007) Nat Rev Cancer, 7, pp. 169-181
Kobayashi, S., Boggon, T.J., Dayaram, T., Janne, P.A., Kocher, O., Meyerson, M., Johnson, B.E., Halmos, B., EGFR mutation and resistance of non-small-cell lung cancer to gefitinib (2005) New England Journal of Medicine, 352 (8), pp. 786-792. , DOI 10.1056/NEJMoa044238
Engelman, J.A., Janne, P.A., Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer (2008) Clin Cancer Res, 14, pp. 2895-2899
Yun, C.-H., Mengwasser, K.E., Toms, A.V., Woo, M.S., Greulich, H., Wong, K.-K., Meyerson, M., Eck, M.J., The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP (2008) Proceedings of the National Academy of Sciences of the United States of America, 105 (6), pp. 2070-2075. , http://www.pnas.org/cgi/reprint/105/6/2070, DOI 10.1073/pnas.0709662105
Zhou, W., Ercan, D., Chen, L., Novel mutant-selective EGFR kinase inhibitors against EGFR T790M (2009) Nature, 462, pp. 1070-1074
Engelman, J.A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Joon, O.P., Lindeman, N., Janne, P.A., MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling (2007) Science, 316 (5827), pp. 1039-1043. , DOI 10.1126/science.1141478
Bean, J., Brennan, C., Shih, J.Y., MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib (2007) Proc Natl Acad Sci USA, 104, pp. 20932-20937
Sequist, L.V., Von Pawel, J., Garmey, E.G., Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer (2011) J Clin Oncol, 29, pp. 3307-3315
Deng, J., Shimamura, T., Perera, S., Proapoptotic BH3-only BCL-2 family protein BIM connects death signaling from epidermal growth factor receptor inhibition to the mitochondrion (2007) Cancer Res, 67, pp. 11867-11875
Costa, D.B., Halmos, B., Kumar, A., BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations (2007) PLoS Med, 4, pp. 1669-1679
Kuroda, J., Puthalakath, H., Cragg, M.S., Kelly, P.N., Bouillet, P., Huang, D.C.S., Kimura, S., Strasser, A., Bim and Bad mediated imatinib-induced killing of Bcr/Abl + leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic (2006) Proceedings of the National Academy of Sciences of the United States of America, 103 (40), pp. 14907-14912. , DOI 10.1073/pnas.0606176103
Gong, Y., Somwar, R., Politi, K., Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas (2007) PLoS Med, 4, pp. e294
Tan, N., Malek, M., Zha, J., Navitoclax enhances the efficacy of taxanes in non-small cell lung cancer models (2011) Clin Cancer Res, 17, pp. 1394-1404
Gandhi, L., Camidge, D.R., Ribeiro De Oliveira, M., Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors (2011) J Clin Oncol, 29, pp. 909-916
Zannetti, A., Iommelli, F., Fonti, R., Gefitinib induction of in vivo detectable signals by Bcl-2/Bcl-xL modulation of inositol trisphosphate receptor type 3 (2008) Clin Cancer Res, 14, pp. 5209-5219
Oh, S.J., Mosdzianowski, C., Chi, D.Y., Fully automated synthesis system of 3′-deoxy-3′-[ 18F]fluorothymidine (2004) Nucl Med Biol, 31, pp. 803-809
Waldherr, C., Mellinghoff, I.K., Tran, C., Halpern, B.S., Rozengurt, N., Safaei, A., Weber, W.A., Czernin, J., Monitoring antiproliferative responses to kinase inhibitor therapy in mice with 3′-deoxy-3′- 18F-fluorothymidine PET (2005) Journal of Nuclear Medicine, 46 (1), pp. 114-120
Wang, Y., Seidel, J., Tsui, B.M.W., Vaquero, J.J., Pomper, M.G., Performance evaluation of the GE healthcare eXplore VISTA dual-ring small-animal PET scanner (2006) Journal of Nuclear Medicine, 47 (11), pp. 1891-1900. , http://jnm.snmjournals.org/cgi/reprint/47/11/1891
Tseng, J.R., Kang, K.W., Dandekar, M., Preclinical efficacy of the c-Met inhibitor CE-355621 in a U87 MG mouse xenograft model evaluated by 18F-FDG small-animal PET (2008) J Nucl Med, 49, pp. 129-134
Wei, L.H., Su, H., Hildebrandt, I.J., Changes in tumor metabolism as readout for mammalian target of rapamycin kinase inhibition by rapamycin in glioblastoma (2008) Clin Cancer Res, 14, pp. 3416-3426
Zannetti, A., Del, V.S., Carriero, M.V., Fonti, R., Franco, P., Botti, G., D'Aiuto, G., Salvatore, M., Coordinate up-regulation of Sp1 DNA-binding activity and urokinase receptor expression in breast carcinoma (2000) Cancer Research, 60 (6), pp. 1546-1551
Ullrich, R.T., Zander, T., Neumaier, B., Early detection of erlotinib treatment response in NSCLC by 3′-deoxy-3′-[F]-fluoro-l-thymidine ([F]FLT) positron emission tomography (PET) (2008) PLoS One, 3, pp. e3908
Sequist, L.V., Waltman, B.A., Dias-Santagata, D., Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors (2011) Sci Transl Med, 3, pp. 75ra26
Zander, T., Scheffler, M., Nogova, L., Early prediction of nonprogression in advanced non-small-cell lung cancer treated with erlotinib by using [ 18F]fluorodeoxyglucose and [ 18F]fluorothymidine positron emission tomography (2011) J Clin Oncol, 29, pp. 1701-1708
Cullinane, C., Dorow, D.S., Jackson, S., Differential 18F-FDG and 3′-deoxy-3′- 18F-fluorothymidine PET responses to pharmacologic inhibition of the c-MET receptor in preclinical tumor models (2011) J Nucl Med, 52, pp. 1261-1267
Yang, M., Gao, H., Yan, Y., PET imaging of early response to the tyrosine kinase inhibitor ZD4190 (2011) Eur J Nucl Med Mol Imaging, 38, pp. 1237-1247
Gazdar, A. F., Activating and resistance mutations of EGFR in non-small-cell lung cancer: Role in clinical response to EGFR tyrosine kinase inhibitors (2009) Oncogene, 28 (SUPPL.), pp. S24-S31
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haber, D. A., Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non-Small-Cell Lung Cancer to Gefitinib (2004) New England Journal of Medicine, 350 (21), pp. 2129-2139. , DOI 10. 1056/NEJMoa040938
Paez, J. G., Janne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Meyerson, M., EGFR mutations in lung, cancer: Correlation with clinical response to gefitinib therapy (2004) Science, 304 (5676), pp. 1497-1500. , DOI 10. 1126/science. 1099314
Sharma, S. V., Bell, D. W., Settleman, J., Epidermal growth factor receptor mutations in lung cancer (2007) Nat Rev Cancer, 7, pp. 169-181
Engelman, J. A., Janne, P. A., Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer (2008) Clin Cancer Res, 14, pp. 2895-2899
Yun, C. -H., Mengwasser, K. E., Toms, A. V., Woo, M. S., Greulich, H., Wong, K. -K., Meyerson, M., Eck, M. J., The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP (2008) Proceedings of the National Academy of Sciences of the United States of America, 105 (6), pp. 2070-2075. , http: //www. pnas. org/cgi/reprint/105/6/2070, DOI 10. 1073/pnas. 0709662105
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Joon, O. P., Lindeman, N., Janne, P. A., MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling (2007) Science, 316 (5827), pp. 1039-1043. , DOI 10. 1126/science. 1141478
Sequist, L. V., Von Pawel, J., Garmey, E. G., Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer (2011) J Clin Oncol, 29, pp. 3307-3315
Costa, D. B., Halmos, B., Kumar, A., BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations (2007) PLoS Med, 4, pp. 1669-1679
Oh, S. J., Mosdzianowski, C., Chi, D. Y., Fully automated synthesis system of 3 -deoxy-3 - [18F] fluorothymidine (2004) Nucl Med Biol, 31, pp. 803-809
Tseng, J. R., Kang, K. W., Dandekar, M., Preclinical efficacy of the c-Met inhibitor CE-355621 in a U87 MG mouse xenograft model evaluated by 18F-FDG small-animal PET (2008) J Nucl Med, 49, pp. 129-134
Wei, L. H., Su, H., Hildebrandt, I. J., Changes in tumor metabolism as readout for mammalian target of rapamycin kinase inhibition by rapamycin in glioblastoma (2008) Clin Cancer Res, 14, pp. 3416-3426
Ullrich, R. T., Zander, T., Neumaier, B., Early detection of erlotinib treatment response in NSCLC by 3 -deoxy-3 - [F] -fluoro-l-thymidine ([F] FLT) positron emission tomography (PET) (2008) PLoS One, 3, pp. e3908
Sequist, L. V., Waltman, B. A., Dias-Santagata, D., Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors (2011) Sci Transl Med, 3, pp. 75ra26
3'-deoxy-3'-18F-fluorothymidine (FLT) PET/CT to guide therapy with epidermal growth factor receptor (EGFR) antagonists and Bcl-xL inhibitors in non-small cell lung cancer
Epidermal growth factor receptor (EGFR) mutational status, activation of downstream signaling, and effective apoptotic cascade are all factors that may affect the tumor response to EGFR tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer (NSCLC). Here we test whether 3′-deoxy-3′- 18F-fluorothymidine ( 18F-FLT) PET/CT can provide clues for the selection of patients with NSCLC as candidates for treatment with reversible and irreversible EGFR TKIs or combination treatment with Bcl-x L inhibitors. Methods: HCC827, H1975, and H1650 NSCLC cells were subcutaneously injected into flanks of nude mice. Tumor-bearing animals were treated daily for 3 d by oral gavage with erlotinib at 50 and 150 mg/kg, CL-387,785 (an irreversible EGFR TKI) at 50 mg/kg, WZ4002 (a more potent irreversible EGFR TKI) at 25 and 50 mg/kg, ABT-263 (a Bcl-x Linhibitor) at 6.25 mg/kg, and a combination of erlotinib (50 mg/kg) and ABT-263 (6.25 mg/kg). Imaging studies were performed before and after 3 d of treatment by intravenous injection of 7.4 MBq of 18F-FLT and small-animal PET/CT of animals at 1 h after injection. Quantitative analysis of reconstructed images of baseline and posttreatment scans was performed, and the percentage change in 18F-FLT uptake in each animal was determined. Tumor sections were tested for Ki67 immunostaining and the percentage of apoptotic cells. Results: Sensitive tumors (HCC827) showed mean decreases in 18F-FLT uptake of 45% and 28% with high- and low-dose regimens of erlotinib, respectively. Resistant NSCLC cells bearing a T790M mutation (H1975) showed mean increases in 18F-FLT uptake of 27% and 33% with high and low doses of erlotinib, respectively. Treatment with CL-387,785, low-dose WZ4002, and high-dose WZ4002 caused mean decreases in tracer uptake of 21%, 26%, and 36%, respectively. NSCLC cells that were resistant because of dysregulation of Bcl-2 family members (H1650) showed mean reductions in 18F-FLT uptake of 49% and 23% with high and low doses of erlotinib, respectively, whereas the addition of ABT-263 did not affect tracer uptake but significantly increased the percentage of apoptotic cells in tumor sections. Conclusion: PET/CT with 18F-FLT may contribute to the selection of patients who may benefit from treatment with reversible and irreversible EGFR TKIs and may provide clues about which patients with NSCLC may be candidates for combination treatment with erlotinib and Bcl-x L inhibitors. Copyright © 2012 by the Society of Nuclear Medicine, Inc.
Epidermal growth factor receptor (EGFR) mutational status, activation of downstream signaling, and effective apoptotic cascade are all factors that may affect the tumor response to EGFR tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer (NSCLC). Here we test whether 3′-deoxy-3′- 18F-fluorothymidine ( 18F-FLT) PET/CT can provide clues for the selection of patients with NSCLC as candidates for treatment with reversible and irreversible EGFR TKIs or combination treatment with Bcl-x L inhibitors. Methods: HCC827, H1975, and H1650 NSCLC cells were subcutaneously injected into flanks of nude mice. Tumor-bearing animals were treated daily for 3 d by oral gavage with erlotinib at 50 and 150 mg/kg, CL-387,785 (an irreversible EGFR TKI) at 50 mg/kg, WZ4002 (a more potent irreversible EGFR TKI) at 25 and 50 mg/kg, ABT-263 (a Bcl-x Linhibitor) at 6.25 mg/kg, and a combination of erlotinib (50 mg/kg) and ABT-263 (6.25 mg/kg). Imaging studies were performed before and after 3 d of treatment by intravenous injection of 7.4 MBq of 18F-FLT and small-animal PET/CT of animals at 1 h after injection. Quantitative analysis of reconstructed images of baseline and posttreatment scans was performed, and the percentage change in 18F-FLT uptake in each animal was determined. Tumor sections were tested for Ki67 immunostaining and the percentage of apoptotic cells. Results: Sensitive tumors (HCC827) showed mean decreases in 18F-FLT uptake of 45% and 28% with high- and low-dose regimens of erlotinib, respectively. Resistant NSCLC cells bearing a T790M mutation (H1975) showed mean increases in 18F-FLT uptake of 27% and 33% with high and low doses of erlotinib, respectively. Treatment with CL-387,785, low-dose WZ4002, and high-dose WZ4002 caused mean decreases in tracer uptake of 21%, 26%, and 36%, respectively. NSCLC cells that were resistant because of dysregulation of Bcl-2 family members (H1650) showed mean reductions in 18F-FLT uptake of 49% and 23% with high and low doses of erlotinib, respectively, whereas the addition of ABT-263 did not affect tracer uptake but significantly increased the percentage of apoptotic cells in tumor sections. Conclusion: PET/CT with 18F-FLT may contribute to the selection of patients who may benefit from treatment with reversible and irreversible EGFR TKIs and may provide clues about which patients with NSCLC may be candidates for combination treatment with erlotinib and Bcl-x L inhibitors. Copyright © 2012 by the Society of Nuclear Medicine, Inc.
3'-deoxy-3'-18F-fluorothymidine (FLT) PET/CT to guide therapy with epidermal growth factor receptor (EGFR) antagonists and Bcl-xL inhibitors in non-small cell lung cancer
| ▼ Translational Molecular Imaging in Cancer |
| ▼ Molecular imaging for personalized therapy in oncology |
3'-deoxy-3'-18F-fluorothymidine (FLT) PET/CT to guide therapy with epidermal growth factor receptor (EGFR) antagonists and Bcl-xL inhibitors in non-small cell lung cancer
Other filter: ([btitle,keywords] "Lung Cancer" OR [bti ...
Monti S, Xu T, Liao Z, Mohan R, Cella L, Palma G
* On the interplay between dosiomics and genomics in radiation-induced lymphopenia of lung cancer patients (18 views)
Radiother Oncol (ISSN: 0167-8140linking), 2022 Feb; 167: 219-225.
Impact Factor: 6.28
View Export to BibTeX Export to EndNote
Cella L, Monti S, Thor M, Rimner A, Deasy JO, Palma G
* Radiation-Induced Dyspnea in Lung Cancer Patients Treated with Stereotactic Body Radiation Therapy (15 views)
Cancers (ISSN: 2072-6694linking), 2021 Jul 25; 13(15): N/D-N/D.
Impact Factor: 6.126
View Export to BibTeX Export to EndNote
Cella L, Monti S, Xu T, Liuzzi R, Stanzione A, Durante M, Mohan R, Liao Z, Palma G
* Probing thoracic dose patterns associated to pericardial effusion and mortality in patients treated with photons and protons for locally advanced non-small-cell lung cancer (104 views)
Radiother Oncol (ISSN: 0167-8140linking, 1879-0887), 2021 May 9; 160: 148-158.
Impact Factor: 4.856
View Export to BibTeX Export to EndNote
Iommelli F, De Rosa V, Terlizzi C, Fonti R, Camerlingo R, Stoppelli MP, Stewart CA, Byers LA, Piwnica-worms D, Del Vecchio S
* A Reversible Shift of Driver Dependence from EGFR to Notch1 in Non-Small Cell Lung Cancer as a Cause of Resistance to Tyrosine Kinase Inhibitors (24 views)
Cancers (ISSN: 2072-6694linking), 2021 Apr 22; 13(9): N/D-N/D.
Impact Factor: 6.126
View Export to BibTeX Export to EndNote
De Rosa V, Fonti R, Del Vecchio S, Iommelli F
* Non-invasive detection of epithelial mesenchymal transition phenotype and metastatic dissemination of lung cancer by liquid biopsy (37 views) (PDF 14 views)
Exploration Of Targeted Anti-Tumor Therapy, 2021 Mar; N/D: 36-47.
Impact Factor: 0
View Export to BibTeX Export to EndNote
Pellegrino S, Fonti R, Pulcrano A, Del Vecchio S
* PET-Based Volumetric Biomarkers for Risk Stratification of Non-Small Cell Lung Cancer Patients (7 views)
Diagnostics (ISSN: 2075-4418linking, 2075-4418electronic), 2021 Jan 30; 11(2): N/D-N/D.
Impact Factor: 3.706
View Export to BibTeX Export to EndNote
Pellegrino S, Fonti R, Mazziotti E, Piccin L, Mozzillo E, Damiano V, Matano E, De Placido S, Del Vecchio S
* Total metabolic tumor volume by 18F-FDG PET/CT for the prediction of outcome in patients with non-small cell lung cancer (92 views)
Ann Nucl Med (ISSN: 0914-7187linking), 2019 Dec; 33(12): 937-944.
Impact Factor: 1.41
View Export to BibTeX Export to EndNote
Palma G, Monti S, Xu T, Scifoni E, Yang P, Hahn SM, Durante M, Mohan R, Liao Z, Cella L
* Spatial Dose Patterns Associated With Radiation Pneumonitis in a Randomized Trial Comparing Intensity-Modulated Photon Therapy With Passive Scattering Proton Therapy for Locally Advanced Non-Small Cell Lung Cancer (132 views)
Int J Radiat Oncol (ISSN: 0360-3016linking, 1879-355x), 2019 Aug 1; 104(5): 1124-1132.
Impact Factor: 5.859
View Export to BibTeX Export to EndNote
Palma G, Monti S, Thor M, Rimner A, Deasy JO, Cella L
* Spatial signature of dose patterns associated with acute radiation-induced lung damage in lung cancer patients treated with Stereotactic Body Radiation Therapy (163 views)
Phys Med Biol (ISSN: 0031-9155linking), 2019 Jul 1; N/D: N/D-N/D.
Impact Factor: 3.1
View Export to BibTeX Export to EndNote
Iommelli F, De Rosa V, Terlizzi C, Monti M, Panico M, Fonti R, Del Vecchio S
* Inositol Trisphosphate Receptor Type 3-mediated Enhancement of EGFR and MET Cotargeting Efficacy in Non-Small Cell Lung Cancer Detected by (18)F-fluorothymidine (630 views)
Clin Cancer Res (ISSN: 1078-0432print, 1078-0432linking), 2018 Jul 1; 24(13): 3126-3136.
Impact Factor: 10.199
View Export to BibTeX Export to EndNote
Ciarmiello A, Fonti R, Giovacchini G, Del Vecchio S
* Imaging of immunotherapy response in non-small cell lung cancer: challenges and perspectives (132 views)
Clinical And Translational Imaging, 2018; N/D: N/D-N/D.
Impact Factor: 0
View Export to BibTeX Export to EndNote
De Rosa V, Iommelli F, Monti M, Mainolfi CG, Fonti R, Del Vecchio S
* Early 18F-FDG uptake as a reliable imaging biomarker of T790M-mediated resistance but not MET amplification in non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors (315 views)
Ejnmmi Res, 2016 Dec; 6(1): 74-74.
Impact Factor: 1.761
View Export to BibTeX Export to EndNote
Nappi A, Gallicchio R, Simeon V, Nardelli A, Pelagalli A, Zupa A, Vita G, Venetucci A, Di Cosola M, Barbato F, Storto G
* [F-18] FDG-PET/CT parameters as predictors of outcome in inoperable NSCLC patients (219 views)
Radiol Oncol (ISSN: 1318-2099), 2015 Nov 27; 49(4): 320-326.
Impact Factor: 1.736
View Export to BibTeX Export to EndNote
De Rosa V, Iommelli F, Monti M, Fonti R, Votta G, Stoppelli MP, Del Vecchio S
* Reversal of Warburg Effect and Reactivation of Oxidative Phosphorylation by Differential Inhibition of EGFR Signaling Pathways in Non-Small Cell Lung Cancer (653 views)
Clin Cancer Res (ISSN: 1078-0432, 1078-0432linking, 1078-0432print), 2015 Nov 15; 21(22): 5110-5120.
Impact Factor: 8.738
View Export to BibTeX Export to EndNote
Morra F, Luise C, Visconti R, Staibano S, Merolla F, Ilardi G, Guggino G, Paladino S, Sarnataro D, Franco R, Monaco R, Zitomarino F, Pacelli R, Monaco G, Rocco G, Cerrato A, Linardopoulos S, Muller MT, Celetti A
* New therapeutic perspectives in CCDC6 deficient lung cancer cells (462 views)
Int J Cancer (ISSN: 0020-7136), 2015; 136(9): 2146-2157.
Impact Factor: 5.531
View Export to BibTeX Export to EndNote
De Rosa V, Iommelli F, Monti M, Fonti R, Del Vecchio S
* Early reduction of 18F-FDG uptake in non-small lung cancer treated with EGFR tyrosine kinase inhibitors reflects reversal of Warburg effect and reactivation of oxidative phosphorylation (275 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 1619-7070print), 2014 Oct; 41: N/D-N/D.
Impact Factor: 5.383
View Export to BibTeX Export to EndNote
Iommelli F, De Rosa V, Gargiulo S, Panico M, Monti M, Gramanzini M, Fonti R, Del Vecchio S
* Monitoring Reversal of Concurrent Mechanisms of Resistance to EGFR TKIs in Non-Small Cell Lung Cancer by 18F-FLT PET/CT (292 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 1619-7070print), 2014 Oct; 41: N/D-N/D.
Impact Factor: 5.383
View Export to BibTeX Export to EndNote
Iommelli F, De Rosa V, Gargiulo S, Panico M, Monti M, Greco A, Gramanzini M, Ortosecco G, Fonti R, Brunetti A, Del Vecchio S
* Monitoring Reversal of MET-Mediated Resistance to EGFR Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer Using 3 '-Deoxy-3 '-[F-18]-Fluorothymidine Positron Emission Tomography (513 views)
Clin Cancer Res (ISSN: 1078-0432, 1078-0432linking, 1078-0432print), 2014 Sep 15; 20(18): 4806-4815.
Impact Factor: 8.722
View Export to BibTeX Export to EndNote
Gallicchio R, Giacomobono S, Nardelli A, Pellegrino T, Simeon V, Gattozzi D, Maddalena F, Mainenti PP, Storto G
* Palliative Treatment Of Bone Metastases With Samarium-153 Edtmp At Onset Of Pain (395 views)
J Bone Miner Metab (ISSN: 0914-8779), 2014 Jul; 32(4): 434-440.
Impact Factor: 2.46
View Export to BibTeX Export to EndNote
Nguyen XC, Nguyen VK, Tran MT, Maurea S, Salvatore M
* Prognostic Value of Fluoro-D-glucose Uptake of Primary Tumor and Metastatic Lesions in Advanced Nonsmall Cell Lung Cancer (213 views)
World Journal Of Nuclear Medicine (ISSN: 1450-1147), 2014 May; 13(2): 112-119.
Impact Factor: 5.563
View Export to BibTeX Export to EndNote
Pedicini P, Strigari L, Benassi M, Caivano R, Fiorentino A, Nappi A, Salvatore M, Storto G
* Critical dose and toxicity index of organs at risk in radiotherapy: analyzing the calculated effects of modified dose fractionation in non-small cell lung cancer (522 views)
Med Dosim (ISSN: 0958-3947, 1873-4022), 2014 Mar; 39(1): 23-30.
Impact Factor: 0.76
View Export to BibTeX Export to EndNote
Iommelli F, De Rosa V, Fonti R, Del Vecchio S
* Molecular Imaging For Detection Of Sensitivity And Resistance To Egfr Tyrosine Kinase Inhibitors In Non-Small Cell Lung Cancer (303 views)
Clin Transl Imaging (ISSN: 2281-5872print, 2281-7565online), 2014 Feb 20; 2(1): 43-53.
Impact Factor: 0
View Export to BibTeX Export to EndNote
Iommelli F, De Rosa V, Gargiulo S, Panico M, Monti M, Ortosecco G, Greco A, Gramanzini M, Fonti R, Brunetti A, Del Vecchio S
* 18F-FLT PET/CT for Detection of Functional Cross-talk between MET and EGFR in Non-small Cell Lung Cancer Resistant to EGFR Inhibitors (371 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2013 Oct; 40: N/D-N/D.
Impact Factor: 5.217
View Export to BibTeX Export to EndNote
De Rosa V, Iommelli F, Votta G, Monti M, Ortosecco G, Fonti R, Mainolfi C, Stoppelli M, Del Vecchio S
* Changes of Glycolytic Pathway in Response to Efficient Inhibition of EGFR Signaling in Non-small Cell Lung Cancer (NSCLC) (272 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2013 Oct; 40: N/D-N/D.
Impact Factor: 5.217
View Export to BibTeX Export to EndNote
Bera S, De Rosa V, Rachidi W, Diamond AM
* Does a role for selenium in DNA damage repair explain apparent controversies in its use in chemoprevention? (609 views)
Mutagenesismutagenesis (ISSN: 0267-8357, 1464-3804electronic, 0267-8357linking), 2013 Mar; 28(2): 127-134.
Impact Factor: 3.497
View Export to BibTeX Export to EndNote
Cella L, Conson M, Pressello MC, Molinelli S, Schneider U, Donato V, Orecchia R, Salvatore M, Pacelli R
* Hodgkin's lymphoma emerging radiation treatment techniques: Trade-offs between late radio-induced toxicities and secondary malignant neoplasms (395 views)
Radiat Oncol Radiation Oncology (ISSN: 1748-717x), 2013 Jan 30; 8(1): 22-22.
Impact Factor: 2.36
View Export to BibTeX Export to EndNote
Zannetti A, Iommelli F, De Rosa V, Nardelli A, Ortosecco G, Del Vecchio S
* Combined Imaging with 18F-FLT PET/CT and 99m-Tc-Hynic-Annexin V SPECT for Personalized Therapy with EGFR Antagonists and Bcl-xL Inhibitors in Non-Small Cell Lung Cancer (393 views)
European Journal Of Cancer (ISSN: 0959-8049), 2012 Nov; 48: N/D-N/D.
Impact Factor: 5.061
View Export to BibTeX Export to EndNote
Zannetti A, Iommelli F, De Rosa V, Salvatore M, Del Vecchio S
* Small animal SPECT with 99m-Tc-Hynic-annexin V for detection of non-small cell lung cancer resistance to EGFR antagonists and its reversal by Bcl-xL inhibitors (402 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2012 Oct; 39: N/D-N/D.
Impact Factor: 5.114
View Export to BibTeX Export to EndNote
Zannetti A, Iommelli F, Speranza A, Salvatore M, Del Vecchio S
* 3'-deoxy-3'-18F-fluorothymidine PET/CT to guide therapy with epidermal growth factor receptor antagonists and Bcl-xL inhibitors in non-small cell lung cancer (525 views)
J Nucl Med (ISSN: 1535-5667, 0161-5505, 1535-5667electronic), 2012 Mar 1; 53(3): 443-450.
Impact Factor: 5.774
View Export to BibTeX Export to EndNote
Zeppa P, Barra E, Napolitano V, Cozzolino I, Troncone G, Picardi M, De Renzo A, Mainenti PP, Vetrani A, Palombini L
* Impact of Endoscopic Ultrasound-Guided Fine Needle Aspiration (EUS-FNA) in Lymph Nodal and Mediastinal Lesions: A Multicenter Experience (580 views)
Diagnostic Cytopathology (ISSN: 8755-1039), 2011 Oct; 39(10): 723-729.
Impact Factor: 1.16
View Export to BibTeX Export to EndNote
Storto G, Di Giorgio E, De Renzo A, Pizzuti LM, Cerciello G, Nardelli A, Capacchione D, Castaldi E, Ortosecco G, Pace L
* Assessment of metabolic activity by PET-CT with F-18-FDG in patients with T-cell lymphoma (516 views)
Br J Haematol (ISSN: 0007-1048, 0007-1048linking, 1365-2141electronic), 2010 Oct; 151(2): 195-197.
Impact Factor: 4.942
View Export to BibTeX Export to EndNote
Del Vecchio S, Zannetti A, Fonti R, Iommelli F, Pizzuti LM, Lettieri A, Salvatore M
* PET/CT in cancer research: From preclinical to clinical applications (617 views)
Contrast Media Mol Imaging (ISSN: 1555-4309, 1555-4309linking), 2010 Jul; 5(4): 190-200.
Impact Factor: 4.02
View Export to BibTeX Export to EndNote
Del Vecchio S, Zannetti A, Fonti R, Iommelli F, Lettieri A, Salvatore M
* Molecular imaging of drug resistance in cancer (438 views)
Minerva Biotecnol (ISSN: 1120-4826), 2009 Mar; 21(1): 31-36.
Impact Factor: 0.268
View Export to BibTeX Export to EndNote
Zannetti A, Iommelli F, Fonti R, Papaccioli A, Sommella J, Lettieri A, Bianco R, Tortora G, Salvatore M, Del Vecchio S
* Imaging of lung cancer resistance to EGFR tyrosine kinase inhibitors through Bcl-2/Bcl-x(L) modulation of inositol trisphosphate receptor type (392 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2008 Oct; 35: N/D-N/D.
Impact Factor: 4.532
View Export to BibTeX Export to EndNote
Zannetti A, Iommelli F, Fonti R, Papaccioli A, Sommella J, Lettieri A, Pirozzi G, Bianco R, Tortora G, Salvatore M, Del Vecchio S
* Gefitinib induction of in vivo detectable signals by Bcl-2/Bcl-xL modulation of inositol trisphosphate receptor type (537 views)
Clin Cancer Res (ISSN: 1078-0432, 1078-0432linking, 1078-0432print), 2008 Aug 15; 14(16): 5209-5219.
Impact Factor: 6.488
View Export to BibTeX Export to EndNote
Zannetti A, Iommelli F, Fonti R, Papaccioli A, Sommella J, Lettieri A, Bianco R, Tortora G, Salvatore M, Del Vecchio S
* Imaging Of Lung Cancer Resistance To Egfr Tyrosine Kinase Inhibitors Trough Bcl-2/Bcl-Xl Modulation Of Inositol Trisphosphate Receptor Type (382 views)
Eur J Nucl Med, 2008; suppl2: N/D-N/D.
Impact Factor: 5.563
View Export to BibTeX Export to EndNote
Zannetti A, Fonti R, Iommelli F, Papaccioli A, Sommella J, Tortora G, Bianco R, Salvatore M, Del Vecchio S
* SPECT imaging of endoplasmic reticulum-mediated tumor response to gefitinib and erlotinib in lung cancer (424 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2007 Oct; 34: 277-309.
Impact Factor: 4.101
View Export to BibTeX Export to EndNote
Del Vecchio S, Zannetti A, Fonti R, Pace L, Salvatore M
* Nuclear imaging in cancer theranostics (616 views)
Q J Nucl Med Mol Im (ISSN: 1824-4785, 1824-4478, 1824-4785linking), 2007 Jun; 51(2): 152-163.
Impact Factor: 1.724
View Export to BibTeX Export to EndNote
Borgatti M, Boyd DD, Lampronti I, Bianchi N, Fabbri E, Saviano M, Romanelli A, Pedone C, Gambari R
* Decoy molecules based on PNA-DNA chimeras and targeting Sp1 transcription factors inhibit the activity of urokinase-type plasminogen activator receptor (uPAR) promoter (438 views)
Oncology Research (ISSN: 0965-0407), 2005; 15(7-8): 373-383.
Impact Factor: 1.844
View Export to BibTeX Export to EndNote
Russo M, Tedesco I, Iacomino G, Palumbo R, Galano G, Russo GL
* Dietary phytochemicals in chemoprevention of cancer (348 views)
Curr Med Chem (ISSN: 1568-0134), 2005; 5(1): 61-72.
Impact Factor: 3.715
View Export to BibTeX Export to EndNote
Del Vecchio S, Zannetti A, Aloj L, Salvatore M
* MIBI as prognostic factor in breast cancer (463 views)
Q J Nucl Med (ISSN: 1124-3937, 1125-0135), 2003 Mar; 47(1): 46-50.
Impact Factor: 2.222
View Export to BibTeX Export to EndNote
Gridelli C, Manzione L, Perrone F, Veltri E, Cioffi R, Caprio MG, Frontini L, Rossi A, Barletta E, Barzelloni ML, Bilancia D, Gallo C
* Carboplatin plus paclitaxel in extensive small cell lung cancer: a multicentre phase 2 study (255 views) (PDF 220 views)
Br J Cancer (ISSN: 0007-0920print, 0007-0920linking), 2001 Jan 5; 84(1): 38-41.
Impact Factor: 3.942
View Export to BibTeX Export to EndNote
Wang H, Maurea S, Mainolfi C, Fiore F, Gravina A, Panico M, Bazzicalupo L, Salvatore M
Tc-99m MIBI scintigraphy in patients with lung cancer comparison with CT and fluorine-18 FDG PET imaging (317 views)
Clin Nucl Med (ISSN: 0363-9762, 1536-0229, 1536-0229electronic), 1997 Apr; 22(4): 243-249.
Impact Factor: 0.34
View Export to BibTeX Export to EndNote
Cappabianca S, Sirignano C, Cangiano G L, Iula G F, Sandomenico F, Schilliro' F, Del Vecchio W
Vascular Infiltration From Lung Cancer: Evaluation With Turbo-Flash Sequence (217 views)
European Radiology, 1997; nd: nd-nd.
Impact Factor: 0
View Export to BibTeX Export to EndNote
Wang H, Maurea S, Mainolfi C, Fiore F, Panico M, Alfano B, Gravina A, Bazzicalupo L, Salvatore M
Tc-99m MIBI imaging in patients with lung cancer: Comparison with CT and fluorine-18 FDG PET studies (299 views)
J Nucl Med (ISSN: 0161-5505, 1535-5667, 1535-5667electronic), 1996 May; 37(5SUPPL.): N/D-N/D.
Impact Factor: 3.491
View Export to BibTeX Export to EndNote
Del Vecchio S, Mansi L, Petrillo A, Camera L, Sofia M, Marra A, Carratú L, Salvatore M
Endobronchial administration of iodine-131 B72. 3 monoclonal antibody in patients with lung cancer (292 views)
Eur J Nucl Med (ISSN: 0340-6997, 1619-7070, 1619-7089), 1991; 18(2): 129-132.
Impact Factor: 2.692
View Export to BibTeX Export to EndNote
DEL VECCHIO S, MANSI L, GAGLIARDI N, PETRILLO A, SOFIA M, CARRATU L, SALVATORE M
INTRABRONCHIAL ADMINISTRATION OF IODINE-131 B72. 3 MONOCLONAL ANTIBODY IN PATIENTS WITH LUNG CANCER (317 views)
Eur J Nucl Med (ISSN: 0340-6997, 1619-7070, 1619-7089), 1988; 14(5-6): N/D-N/D.
Impact Factor: 2.692
View Export to BibTeX Export to EndNote
Alfano B, Coucourde F, Malgieri F, Ragozzino A
PET/CT and radiotherapy (2711 views)
Q J Nucl Med Mol Imaging, 1980 Oct; 50(1): 4-14.
Impact Factor: 0
View Export to BibTeX Export to EndNote
* On the interplay between dosiomics and genomics in radiation-induced lymphopenia of lung cancer patients (18 views)
Radiother Oncol (ISSN: 0167-8140linking), 2022 Feb; 167: 219-225.
Impact Factor: 6.28
View Export to BibTeX Export to EndNote
Cella L, Monti S, Thor M, Rimner A, Deasy JO, Palma G
* Radiation-Induced Dyspnea in Lung Cancer Patients Treated with Stereotactic Body Radiation Therapy (15 views)
Cancers (ISSN: 2072-6694linking), 2021 Jul 25; 13(15): N/D-N/D.
Impact Factor: 6.126
View Export to BibTeX Export to EndNote
Cella L, Monti S, Xu T, Liuzzi R, Stanzione A, Durante M, Mohan R, Liao Z, Palma G
* Probing thoracic dose patterns associated to pericardial effusion and mortality in patients treated with photons and protons for locally advanced non-small-cell lung cancer (104 views)
Radiother Oncol (ISSN: 0167-8140linking, 1879-0887), 2021 May 9; 160: 148-158.
Impact Factor: 4.856
View Export to BibTeX Export to EndNote
Iommelli F, De Rosa V, Terlizzi C, Fonti R, Camerlingo R, Stoppelli MP, Stewart CA, Byers LA, Piwnica-worms D, Del Vecchio S
* A Reversible Shift of Driver Dependence from EGFR to Notch1 in Non-Small Cell Lung Cancer as a Cause of Resistance to Tyrosine Kinase Inhibitors (24 views)
Cancers (ISSN: 2072-6694linking), 2021 Apr 22; 13(9): N/D-N/D.
Impact Factor: 6.126
View Export to BibTeX Export to EndNote
De Rosa V, Fonti R, Del Vecchio S, Iommelli F
* Non-invasive detection of epithelial mesenchymal transition phenotype and metastatic dissemination of lung cancer by liquid biopsy (37 views) (PDF 14 views)
Exploration Of Targeted Anti-Tumor Therapy, 2021 Mar; N/D: 36-47.
Impact Factor: 0
View Export to BibTeX Export to EndNote
Pellegrino S, Fonti R, Pulcrano A, Del Vecchio S
* PET-Based Volumetric Biomarkers for Risk Stratification of Non-Small Cell Lung Cancer Patients (7 views)
Diagnostics (ISSN: 2075-4418linking, 2075-4418electronic), 2021 Jan 30; 11(2): N/D-N/D.
Impact Factor: 3.706
View Export to BibTeX Export to EndNote
Pellegrino S, Fonti R, Mazziotti E, Piccin L, Mozzillo E, Damiano V, Matano E, De Placido S, Del Vecchio S
* Total metabolic tumor volume by 18F-FDG PET/CT for the prediction of outcome in patients with non-small cell lung cancer (92 views)
Ann Nucl Med (ISSN: 0914-7187linking), 2019 Dec; 33(12): 937-944.
Impact Factor: 1.41
View Export to BibTeX Export to EndNote
Palma G, Monti S, Xu T, Scifoni E, Yang P, Hahn SM, Durante M, Mohan R, Liao Z, Cella L
* Spatial Dose Patterns Associated With Radiation Pneumonitis in a Randomized Trial Comparing Intensity-Modulated Photon Therapy With Passive Scattering Proton Therapy for Locally Advanced Non-Small Cell Lung Cancer (132 views)
Int J Radiat Oncol (ISSN: 0360-3016linking, 1879-355x), 2019 Aug 1; 104(5): 1124-1132.
Impact Factor: 5.859
View Export to BibTeX Export to EndNote
Palma G, Monti S, Thor M, Rimner A, Deasy JO, Cella L
* Spatial signature of dose patterns associated with acute radiation-induced lung damage in lung cancer patients treated with Stereotactic Body Radiation Therapy (163 views)
Phys Med Biol (ISSN: 0031-9155linking), 2019 Jul 1; N/D: N/D-N/D.
Impact Factor: 3.1
View Export to BibTeX Export to EndNote
Iommelli F, De Rosa V, Terlizzi C, Monti M, Panico M, Fonti R, Del Vecchio S
* Inositol Trisphosphate Receptor Type 3-mediated Enhancement of EGFR and MET Cotargeting Efficacy in Non-Small Cell Lung Cancer Detected by (18)F-fluorothymidine (630 views)
Clin Cancer Res (ISSN: 1078-0432print, 1078-0432linking), 2018 Jul 1; 24(13): 3126-3136.
Impact Factor: 10.199
View Export to BibTeX Export to EndNote
Ciarmiello A, Fonti R, Giovacchini G, Del Vecchio S
* Imaging of immunotherapy response in non-small cell lung cancer: challenges and perspectives (132 views)
Clinical And Translational Imaging, 2018; N/D: N/D-N/D.
Impact Factor: 0
View Export to BibTeX Export to EndNote
De Rosa V, Iommelli F, Monti M, Mainolfi CG, Fonti R, Del Vecchio S
* Early 18F-FDG uptake as a reliable imaging biomarker of T790M-mediated resistance but not MET amplification in non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors (315 views)
Ejnmmi Res, 2016 Dec; 6(1): 74-74.
Impact Factor: 1.761
View Export to BibTeX Export to EndNote
Nappi A, Gallicchio R, Simeon V, Nardelli A, Pelagalli A, Zupa A, Vita G, Venetucci A, Di Cosola M, Barbato F, Storto G
* [F-18] FDG-PET/CT parameters as predictors of outcome in inoperable NSCLC patients (219 views)
Radiol Oncol (ISSN: 1318-2099), 2015 Nov 27; 49(4): 320-326.
Impact Factor: 1.736
View Export to BibTeX Export to EndNote
De Rosa V, Iommelli F, Monti M, Fonti R, Votta G, Stoppelli MP, Del Vecchio S
* Reversal of Warburg Effect and Reactivation of Oxidative Phosphorylation by Differential Inhibition of EGFR Signaling Pathways in Non-Small Cell Lung Cancer (653 views)
Clin Cancer Res (ISSN: 1078-0432, 1078-0432linking, 1078-0432print), 2015 Nov 15; 21(22): 5110-5120.
Impact Factor: 8.738
View Export to BibTeX Export to EndNote
Morra F, Luise C, Visconti R, Staibano S, Merolla F, Ilardi G, Guggino G, Paladino S, Sarnataro D, Franco R, Monaco R, Zitomarino F, Pacelli R, Monaco G, Rocco G, Cerrato A, Linardopoulos S, Muller MT, Celetti A
* New therapeutic perspectives in CCDC6 deficient lung cancer cells (462 views)
Int J Cancer (ISSN: 0020-7136), 2015; 136(9): 2146-2157.
Impact Factor: 5.531
View Export to BibTeX Export to EndNote
De Rosa V, Iommelli F, Monti M, Fonti R, Del Vecchio S
* Early reduction of 18F-FDG uptake in non-small lung cancer treated with EGFR tyrosine kinase inhibitors reflects reversal of Warburg effect and reactivation of oxidative phosphorylation (275 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 1619-7070print), 2014 Oct; 41: N/D-N/D.
Impact Factor: 5.383
View Export to BibTeX Export to EndNote
Iommelli F, De Rosa V, Gargiulo S, Panico M, Monti M, Gramanzini M, Fonti R, Del Vecchio S
* Monitoring Reversal of Concurrent Mechanisms of Resistance to EGFR TKIs in Non-Small Cell Lung Cancer by 18F-FLT PET/CT (292 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 1619-7070print), 2014 Oct; 41: N/D-N/D.
Impact Factor: 5.383
View Export to BibTeX Export to EndNote
Iommelli F, De Rosa V, Gargiulo S, Panico M, Monti M, Greco A, Gramanzini M, Ortosecco G, Fonti R, Brunetti A, Del Vecchio S
* Monitoring Reversal of MET-Mediated Resistance to EGFR Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer Using 3 '-Deoxy-3 '-[F-18]-Fluorothymidine Positron Emission Tomography (513 views)
Clin Cancer Res (ISSN: 1078-0432, 1078-0432linking, 1078-0432print), 2014 Sep 15; 20(18): 4806-4815.
Impact Factor: 8.722
View Export to BibTeX Export to EndNote
Gallicchio R, Giacomobono S, Nardelli A, Pellegrino T, Simeon V, Gattozzi D, Maddalena F, Mainenti PP, Storto G
* Palliative Treatment Of Bone Metastases With Samarium-153 Edtmp At Onset Of Pain (395 views)
J Bone Miner Metab (ISSN: 0914-8779), 2014 Jul; 32(4): 434-440.
Impact Factor: 2.46
View Export to BibTeX Export to EndNote
Nguyen XC, Nguyen VK, Tran MT, Maurea S, Salvatore M
* Prognostic Value of Fluoro-D-glucose Uptake of Primary Tumor and Metastatic Lesions in Advanced Nonsmall Cell Lung Cancer (213 views)
World Journal Of Nuclear Medicine (ISSN: 1450-1147), 2014 May; 13(2): 112-119.
Impact Factor: 5.563
View Export to BibTeX Export to EndNote
Pedicini P, Strigari L, Benassi M, Caivano R, Fiorentino A, Nappi A, Salvatore M, Storto G
* Critical dose and toxicity index of organs at risk in radiotherapy: analyzing the calculated effects of modified dose fractionation in non-small cell lung cancer (522 views)
Med Dosim (ISSN: 0958-3947, 1873-4022), 2014 Mar; 39(1): 23-30.
Impact Factor: 0.76
View Export to BibTeX Export to EndNote
Iommelli F, De Rosa V, Fonti R, Del Vecchio S
* Molecular Imaging For Detection Of Sensitivity And Resistance To Egfr Tyrosine Kinase Inhibitors In Non-Small Cell Lung Cancer (303 views)
Clin Transl Imaging (ISSN: 2281-5872print, 2281-7565online), 2014 Feb 20; 2(1): 43-53.
Impact Factor: 0
View Export to BibTeX Export to EndNote
Iommelli F, De Rosa V, Gargiulo S, Panico M, Monti M, Ortosecco G, Greco A, Gramanzini M, Fonti R, Brunetti A, Del Vecchio S
* 18F-FLT PET/CT for Detection of Functional Cross-talk between MET and EGFR in Non-small Cell Lung Cancer Resistant to EGFR Inhibitors (371 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2013 Oct; 40: N/D-N/D.
Impact Factor: 5.217
View Export to BibTeX Export to EndNote
De Rosa V, Iommelli F, Votta G, Monti M, Ortosecco G, Fonti R, Mainolfi C, Stoppelli M, Del Vecchio S
* Changes of Glycolytic Pathway in Response to Efficient Inhibition of EGFR Signaling in Non-small Cell Lung Cancer (NSCLC) (272 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2013 Oct; 40: N/D-N/D.
Impact Factor: 5.217
View Export to BibTeX Export to EndNote
Bera S, De Rosa V, Rachidi W, Diamond AM
* Does a role for selenium in DNA damage repair explain apparent controversies in its use in chemoprevention? (609 views)
Mutagenesismutagenesis (ISSN: 0267-8357, 1464-3804electronic, 0267-8357linking), 2013 Mar; 28(2): 127-134.
Impact Factor: 3.497
View Export to BibTeX Export to EndNote
Cella L, Conson M, Pressello MC, Molinelli S, Schneider U, Donato V, Orecchia R, Salvatore M, Pacelli R
* Hodgkin's lymphoma emerging radiation treatment techniques: Trade-offs between late radio-induced toxicities and secondary malignant neoplasms (395 views)
Radiat Oncol Radiation Oncology (ISSN: 1748-717x), 2013 Jan 30; 8(1): 22-22.
Impact Factor: 2.36
View Export to BibTeX Export to EndNote
Zannetti A, Iommelli F, De Rosa V, Nardelli A, Ortosecco G, Del Vecchio S
* Combined Imaging with 18F-FLT PET/CT and 99m-Tc-Hynic-Annexin V SPECT for Personalized Therapy with EGFR Antagonists and Bcl-xL Inhibitors in Non-Small Cell Lung Cancer (393 views)
European Journal Of Cancer (ISSN: 0959-8049), 2012 Nov; 48: N/D-N/D.
Impact Factor: 5.061
View Export to BibTeX Export to EndNote
Zannetti A, Iommelli F, De Rosa V, Salvatore M, Del Vecchio S
* Small animal SPECT with 99m-Tc-Hynic-annexin V for detection of non-small cell lung cancer resistance to EGFR antagonists and its reversal by Bcl-xL inhibitors (402 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2012 Oct; 39: N/D-N/D.
Impact Factor: 5.114
View Export to BibTeX Export to EndNote
Zannetti A, Iommelli F, Speranza A, Salvatore M, Del Vecchio S
* 3'-deoxy-3'-18F-fluorothymidine PET/CT to guide therapy with epidermal growth factor receptor antagonists and Bcl-xL inhibitors in non-small cell lung cancer (525 views)
J Nucl Med (ISSN: 1535-5667, 0161-5505, 1535-5667electronic), 2012 Mar 1; 53(3): 443-450.
Impact Factor: 5.774
View Export to BibTeX Export to EndNote
Zeppa P, Barra E, Napolitano V, Cozzolino I, Troncone G, Picardi M, De Renzo A, Mainenti PP, Vetrani A, Palombini L
* Impact of Endoscopic Ultrasound-Guided Fine Needle Aspiration (EUS-FNA) in Lymph Nodal and Mediastinal Lesions: A Multicenter Experience (580 views)
Diagnostic Cytopathology (ISSN: 8755-1039), 2011 Oct; 39(10): 723-729.
Impact Factor: 1.16
View Export to BibTeX Export to EndNote
Storto G, Di Giorgio E, De Renzo A, Pizzuti LM, Cerciello G, Nardelli A, Capacchione D, Castaldi E, Ortosecco G, Pace L
* Assessment of metabolic activity by PET-CT with F-18-FDG in patients with T-cell lymphoma (516 views)
Br J Haematol (ISSN: 0007-1048, 0007-1048linking, 1365-2141electronic), 2010 Oct; 151(2): 195-197.
Impact Factor: 4.942
View Export to BibTeX Export to EndNote
Del Vecchio S, Zannetti A, Fonti R, Iommelli F, Pizzuti LM, Lettieri A, Salvatore M
* PET/CT in cancer research: From preclinical to clinical applications (617 views)
Contrast Media Mol Imaging (ISSN: 1555-4309, 1555-4309linking), 2010 Jul; 5(4): 190-200.
Impact Factor: 4.02
View Export to BibTeX Export to EndNote
Del Vecchio S, Zannetti A, Fonti R, Iommelli F, Lettieri A, Salvatore M
* Molecular imaging of drug resistance in cancer (438 views)
Minerva Biotecnol (ISSN: 1120-4826), 2009 Mar; 21(1): 31-36.
Impact Factor: 0.268
View Export to BibTeX Export to EndNote
Zannetti A, Iommelli F, Fonti R, Papaccioli A, Sommella J, Lettieri A, Bianco R, Tortora G, Salvatore M, Del Vecchio S
* Imaging of lung cancer resistance to EGFR tyrosine kinase inhibitors through Bcl-2/Bcl-x(L) modulation of inositol trisphosphate receptor type (392 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2008 Oct; 35: N/D-N/D.
Impact Factor: 4.532
View Export to BibTeX Export to EndNote
Zannetti A, Iommelli F, Fonti R, Papaccioli A, Sommella J, Lettieri A, Pirozzi G, Bianco R, Tortora G, Salvatore M, Del Vecchio S
* Gefitinib induction of in vivo detectable signals by Bcl-2/Bcl-xL modulation of inositol trisphosphate receptor type (537 views)
Clin Cancer Res (ISSN: 1078-0432, 1078-0432linking, 1078-0432print), 2008 Aug 15; 14(16): 5209-5219.
Impact Factor: 6.488
View Export to BibTeX Export to EndNote
Zannetti A, Iommelli F, Fonti R, Papaccioli A, Sommella J, Lettieri A, Bianco R, Tortora G, Salvatore M, Del Vecchio S
* Imaging Of Lung Cancer Resistance To Egfr Tyrosine Kinase Inhibitors Trough Bcl-2/Bcl-Xl Modulation Of Inositol Trisphosphate Receptor Type (382 views)
Eur J Nucl Med, 2008; suppl2: N/D-N/D.
Impact Factor: 5.563
View Export to BibTeX Export to EndNote
Zannetti A, Fonti R, Iommelli F, Papaccioli A, Sommella J, Tortora G, Bianco R, Salvatore M, Del Vecchio S
* SPECT imaging of endoplasmic reticulum-mediated tumor response to gefitinib and erlotinib in lung cancer (424 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2007 Oct; 34: 277-309.
Impact Factor: 4.101
View Export to BibTeX Export to EndNote
Del Vecchio S, Zannetti A, Fonti R, Pace L, Salvatore M
* Nuclear imaging in cancer theranostics (616 views)
Q J Nucl Med Mol Im (ISSN: 1824-4785, 1824-4478, 1824-4785linking), 2007 Jun; 51(2): 152-163.
Impact Factor: 1.724
View Export to BibTeX Export to EndNote
Borgatti M, Boyd DD, Lampronti I, Bianchi N, Fabbri E, Saviano M, Romanelli A, Pedone C, Gambari R
* Decoy molecules based on PNA-DNA chimeras and targeting Sp1 transcription factors inhibit the activity of urokinase-type plasminogen activator receptor (uPAR) promoter (438 views)
Oncology Research (ISSN: 0965-0407), 2005; 15(7-8): 373-383.
Impact Factor: 1.844
View Export to BibTeX Export to EndNote
Russo M, Tedesco I, Iacomino G, Palumbo R, Galano G, Russo GL
* Dietary phytochemicals in chemoprevention of cancer (348 views)
Curr Med Chem (ISSN: 1568-0134), 2005; 5(1): 61-72.
Impact Factor: 3.715
View Export to BibTeX Export to EndNote
Del Vecchio S, Zannetti A, Aloj L, Salvatore M
* MIBI as prognostic factor in breast cancer (463 views)
Q J Nucl Med (ISSN: 1124-3937, 1125-0135), 2003 Mar; 47(1): 46-50.
Impact Factor: 2.222
View Export to BibTeX Export to EndNote
Gridelli C, Manzione L, Perrone F, Veltri E, Cioffi R, Caprio MG, Frontini L, Rossi A, Barletta E, Barzelloni ML, Bilancia D, Gallo C
* Carboplatin plus paclitaxel in extensive small cell lung cancer: a multicentre phase 2 study (255 views) (PDF 220 views)
Br J Cancer (ISSN: 0007-0920print, 0007-0920linking), 2001 Jan 5; 84(1): 38-41.
Impact Factor: 3.942
View Export to BibTeX Export to EndNote
Wang H, Maurea S, Mainolfi C, Fiore F, Gravina A, Panico M, Bazzicalupo L, Salvatore M
Tc-99m MIBI scintigraphy in patients with lung cancer comparison with CT and fluorine-18 FDG PET imaging (317 views)
Clin Nucl Med (ISSN: 0363-9762, 1536-0229, 1536-0229electronic), 1997 Apr; 22(4): 243-249.
Impact Factor: 0.34
View Export to BibTeX Export to EndNote
Cappabianca S, Sirignano C, Cangiano G L, Iula G F, Sandomenico F, Schilliro' F, Del Vecchio W
Vascular Infiltration From Lung Cancer: Evaluation With Turbo-Flash Sequence (217 views)
European Radiology, 1997; nd: nd-nd.
Impact Factor: 0
View Export to BibTeX Export to EndNote
Wang H, Maurea S, Mainolfi C, Fiore F, Panico M, Alfano B, Gravina A, Bazzicalupo L, Salvatore M
Tc-99m MIBI imaging in patients with lung cancer: Comparison with CT and fluorine-18 FDG PET studies (299 views)
J Nucl Med (ISSN: 0161-5505, 1535-5667, 1535-5667electronic), 1996 May; 37(5SUPPL.): N/D-N/D.
Impact Factor: 3.491
View Export to BibTeX Export to EndNote
Del Vecchio S, Mansi L, Petrillo A, Camera L, Sofia M, Marra A, Carratú L, Salvatore M
Endobronchial administration of iodine-131 B72. 3 monoclonal antibody in patients with lung cancer (292 views)
Eur J Nucl Med (ISSN: 0340-6997, 1619-7070, 1619-7089), 1991; 18(2): 129-132.
Impact Factor: 2.692
View Export to BibTeX Export to EndNote
DEL VECCHIO S, MANSI L, GAGLIARDI N, PETRILLO A, SOFIA M, CARRATU L, SALVATORE M
INTRABRONCHIAL ADMINISTRATION OF IODINE-131 B72. 3 MONOCLONAL ANTIBODY IN PATIENTS WITH LUNG CANCER (317 views)
Eur J Nucl Med (ISSN: 0340-6997, 1619-7070, 1619-7089), 1988; 14(5-6): N/D-N/D.
Impact Factor: 2.692
View Export to BibTeX Export to EndNote
Alfano B, Coucourde F, Malgieri F, Ragozzino A
PET/CT and radiotherapy (2711 views)
Q J Nucl Med Mol Imaging, 1980 Oct; 50(1): 4-14.
Impact Factor: 0
View Export to BibTeX Export to EndNote
48 Records (37 excluding Abstracts).
Total impact factor: 179.675 (132.022 excluding Abstracts).
Total 5 year impact factor: 161.907 (112.135 excluding Abstracts).
Total impact factor: 179.675 (132.022 excluding Abstracts).
Total 5 year impact factor: 161.907 (112.135 excluding Abstracts).
614 views. Last view on Tuesday 14 February 2023, 21:49:13
ibb.cnr.it
